Becton, Dickinson and Company (NYSE:BDX) to Issue $0.91 Quarterly Dividend

Becton, Dickinson and Company (NYSE:BDXGet Rating) declared a quarterly dividend on Tuesday, January 24th, RTT News reports. Shareholders of record on Friday, March 10th will be paid a dividend of 0.91 per share by the medical instruments supplier on Friday, March 31st. This represents a $3.64 annualized dividend and a dividend yield of 1.48%.

Becton, Dickinson and has raised its dividend payment by an average of 4.3% annually over the last three years and has increased its dividend every year for the last 51 years. Becton, Dickinson and has a payout ratio of 27.3% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Becton, Dickinson and to earn $13.29 per share next year, which means the company should continue to be able to cover its $3.64 annual dividend with an expected future payout ratio of 27.4%.

Becton, Dickinson and Trading Down 1.5 %

Shares of BDX traded down $3.83 during midday trading on Tuesday, hitting $245.75. The stock had a trading volume of 893,175 shares, compared to its average volume of 1,128,112. Becton, Dickinson and has a fifty-two week low of $215.90 and a fifty-two week high of $280.62. The business has a 50-day simple moving average of $248.25 and a two-hundred day simple moving average of $243.88. The firm has a market cap of $69.86 billion, a P/E ratio of 42.45, a price-to-earnings-growth ratio of 2.23 and a beta of 0.58. The company has a current ratio of 1.04, a quick ratio of 0.63 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its earnings results on Thursday, November 10th. The medical instruments supplier reported $2.75 EPS for the quarter, topping the consensus estimate of $2.73 by $0.02. Becton, Dickinson and had a net margin of 9.16% and a return on equity of 14.47%. The company had revenue of $4.76 billion during the quarter, compared to analysts’ expectations of $4.72 billion. During the same period last year, the company posted $2.15 earnings per share. The business’s revenue for the quarter was down 6.6% on a year-over-year basis. As a group, equities analysts forecast that Becton, Dickinson and will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Citigroup raised shares of Becton, Dickinson and from a “sell” rating to a “neutral” rating and increased their price target for the stock from $221.00 to $250.00 in a research report on Monday, December 12th. The Goldman Sachs Group reduced their price target on shares of Becton, Dickinson and from $319.00 to $272.00 and set a “buy” rating for the company in a research report on Wednesday, November 23rd. Bank of America raised shares of Becton, Dickinson and from a “neutral” rating to a “buy” rating and increased their price target for the stock from $250.00 to $290.00 in a research report on Tuesday, January 3rd. Evercore ISI reduced their price target on shares of Becton, Dickinson and to $270.00 in a research report on Wednesday, November 16th. Finally, StockNews.com lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $273.82.

Hedge Funds Weigh In On Becton, Dickinson and

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its position in shares of Becton, Dickinson and by 49.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,012,078 shares of the medical instruments supplier’s stock valued at $269,213,000 after purchasing an additional 333,546 shares during the period. Royal Bank of Canada raised its position in shares of Becton, Dickinson and by 33.0% in the first quarter. Royal Bank of Canada now owns 954,814 shares of the medical instruments supplier’s stock valued at $253,980,000 after purchasing an additional 237,004 shares during the period. BNP Paribas Arbitrage SA raised its position in shares of Becton, Dickinson and by 368.2% in the first quarter. BNP Paribas Arbitrage SA now owns 252,323 shares of the medical instruments supplier’s stock valued at $67,118,000 after purchasing an additional 198,435 shares during the period. Eaton Vance Management raised its position in shares of Becton, Dickinson and by 65.6% in the first quarter. Eaton Vance Management now owns 386,728 shares of the medical instruments supplier’s stock valued at $102,869,000 after purchasing an additional 153,222 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Becton, Dickinson and by 56.0% in the first quarter. Renaissance Technologies LLC now owns 181,272 shares of the medical instruments supplier’s stock valued at $48,218,000 after purchasing an additional 65,100 shares during the period. Institutional investors own 87.08% of the company’s stock.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

Recommended Stories

Dividend History for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.